Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets

被引:14
作者
Zhong, Xiaodan [1 ,2 ,3 ]
Tao, Ying [4 ]
Chang, Jian [2 ]
Zhang, Yutong [2 ]
Zhang, Hao [1 ,3 ]
Wang, Linyu [1 ,3 ]
Liu, Yuanning [1 ,3 ]
机构
[1] Jilin Univ, Coll Comp Sci & Technol, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Dept Pediat Oncol, Changchun, Peoples R China
[3] Jilin Univ, Minist Educ, Key Lab Symbol Computat & Knowledge Engn, Changchun, Peoples R China
[4] Jilin Univ, China Japan Union Hosp, Dept Anesthesiol, Changchun, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
immune-related; neuroblastoma; prognosis; validation; lncRNAs; PROMOTES; METASTASIS; GROWTH; CELLS; MYCN;
D O I
10.3389/fonc.2021.631546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prognostic value of immune-related genes and lncRNAs in neuroblastoma has not been elucidated, especially in subgroups with different outcomes. This study aimed to explore immune-related prognostic signatures. Materials and Methods Immune-related prognostic genes and lncRNAs were identified by univariate Cox regression analysis in the training set. The top 20 C-index genes and 17 immune-related lncRNAs were included in prognostic model construction, and random forest and the Least Absolute Shrinkage and Selection Operator (LASSO) regression algorithms were employed to select features. The risk score model was constructed and assessed using the Kaplan-Meier plot and the receiver operating characteristic curve. Functional enrichment analysis of the immune-related lncRNAs was conducted using the STRING database. Results In GSE49710, five immune genes (CDK4, PIK3R1, THRA, MAP2K2, and ULBP2) were included in the risk score five genes (RS5_G) signature, and eleven immune-related lncRNAs (LINC00260, FAM13A1OS, AGPAT4-IT1, DUBR, MIAT, TSC22D1-AS1, DANCR, MIR137HG, ERC2-IT1, LINC01184, LINC00667) were brought into risk score LncRNAs (RS_Lnc) signature. Patients were divided into high/low-risk score groups by the median. Overall survival and event/progression-free survival time were shortened in patients with high scores, both in training and validation cohorts. The same results were found in subgroups. In grouping ability assessment, the area under the curves (AUCs) in distinguishing different groups ranged from 0.737 to 0.94, better in discriminating MYCN status and high risk in training cohort (higher than 0.9). Multivariate Cox analysis demonstrated that RS5_G and RS_Lnc were the independent risk factors for overall and event/progression-free survival (all p-values <0.001). Correlation analysis showed that RS5_G and RS_Lnc were negatively associated with aDC, CD8+ T cells, but positively correlated with Th2 cells. Functional enrichment analyzes demonstrated that immune-related lncRNAs are mainly enriched in cancer-related pathways and immune-related pathways. Conclusion We identified the immune-related prognostic signature RS5_G and RS_Lnc. The predicting and grouping ability is close to being even better than those reported in other studies, especially in subgroups. This study provided prognostic signatures that may help clinicians to choose optimal treatment strategies and showed a new insight for NB treatment. These results need further biological experiments and clinical validation.
引用
收藏
页数:14
相关论文
共 64 条
  • [1] Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors
    Ahmed, Atif A.
    Zhang, Lei
    Reddivalla, Naresh
    Hetherington, Maxine
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (03) : 165 - 185
  • [2] xCell: digitally portraying the tissue cellular heterogeneity landscape
    Aran, Dvir
    Hu, Zicheng
    Butte, Atul J.
    [J]. GENOME BIOLOGY, 2017, 18
  • [3] MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma
    Beckers, Anneleen
    Van Peer, Gert
    Carter, Daniel R.
    Gartlgruber, Moritz
    Herrmann, Carl
    Agarwal, Saurabh
    Helsmoortel, Hetty H.
    Althoff, Kristina
    Molenaar, Jan J.
    Cheung, Belamy B.
    Schulte, Johannes H.
    Benoit, Yves
    Shohet, Jason M.
    Westermann, Frank
    Marshall, Glenn M.
    Vandesompele, Jo
    De Preter, Katleen
    Speleman, Frank
    [J]. CANCER LETTERS, 2015, 366 (01) : 123 - 132
  • [4] ImmPort, toward repurposing of open access immunological assay data for translational and clinical research
    Bhattacharya, Sanchita
    Dunn, Patrick
    Thomas, Cristel G.
    Smith, Barry
    Schaefer, Henry
    Chen, Jieming
    Hu, Zicheng
    Zalocusky, Kelly A.
    Shankar, Ravi D.
    Shen-Orr, Shai S.
    Thomson, Elizabeth
    Wiser, Jeffrey
    Butte, Atul J.
    [J]. SCIENTIFIC DATA, 2018, 5
  • [5] More than the genes, the tumor microenvironment in neuroblastoma
    Borriello, Lucia
    Seeger, Robert C.
    Asgharzadeh, Shahab
    DeClerck, Yves A.
    [J]. CANCER LETTERS, 2016, 380 (01) : 304 - 314
  • [6] Mechanisms of neuroblastoma regression
    Brodeur, Garrett M.
    Bagatell, Rochelle
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (12) : 704 - 713
  • [7] Long Non-Coding RNA in the Pathogenesis of Cancers
    Chi, Yujing
    Wang, Di
    Wang, Junpei
    Yu, Weidong
    Yang, Jichun
    [J]. CELLS, 2019, 8 (09)
  • [8] The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis
    Domingo-Fernandez, Raquel
    Watters, Karen
    Piskareva, Olga
    Stallings, Raymond L.
    Bray, Isabella
    [J]. PEDIATRIC SURGERY INTERNATIONAL, 2013, 29 (02) : 101 - 119
  • [9] Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
    DuBois, Steven G.
    Marachelian, Araz
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    Groshen, Susan
    Malvar, Jemily
    Bagatell, Rochelle
    Wagner, Lars
    Maris, John M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Czarnecki, Scarlett
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Mosse, Yael P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : 1368 - +
  • [10] An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma
    Formicola, Daniela
    Petrosino, Giuseppe
    Lasorsa, Vito Alessandro
    Pignataro, Piero
    Cimmino, Flora
    Vetrella, Simona
    Longo, Luca
    Tonini, Gian Paolo
    Oberthuer, Andre
    Iolascon, Achille
    Fischer, Matthias
    Capasso, Mario
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14